SI-BONE, Inc. (SIBN)

In the past six months, SI-BONE, Inc. reported earnings that surpassed analysts' expectations, with a revenue of $48.63 million and an EPS of ($0.14). The stock price as of July 31, 2025, was $17.03. On October 24, 2025, the price was $15.49, with a 52-week range of $11.70 to $20.05. Morgan Stanley hosted SI-BONE, Inc. at their 23rd Annual Global Healthcare Conference on September 9, 2025.

The provided information does not contain specific details regarding the demand seasonality for SI-BONE, Inc.'s products and services. The company's growth is driven by physician adoption, international expansion, and a strong innovation pipeline, suggesting a consistent demand. The aging demographic and advancements in healthcare are also noted as factors that will expand minimally invasive markets.

SI-BONE, Inc. is a medical device company specializing in minimally invasive surgical implant systems for musculoskeletal disorders of the sacropelvic anatomy. Its primary product is the iFuse Implant System, designed to fuse the sacroiliac (SI) joint to treat SI joint dysfunction. The company's product portfolio includes iFuse-3D, iFuse-TORQ, iFuse Bedrock Granite Implant System, iFuse TORQ TNT, and iFuse INTRA implants. The company also provides training and educational programs and conducts clinical research studies.

SI-BONE, Inc. develops and commercializes its minimally invasive surgical implant systems in the United States and internationally. The company is headquartered in Santa Clara, California, and markets its products through a direct sales force and third-party sales agents and resellers. It is a global organization with offices worldwide.

SI-BONE has a strong brand reputation as a global leader in technology for the surgical treatment of sacropelvic disorders. The company pioneered the iFuse Implant System in 2009, and its technologies are supported by extensive clinical evidence. SI-BONE is actively involved in research and development and collaborates with leading medical professionals and institutions. The company focuses on innovative, minimally invasive surgical solutions to improve patient lives.

Over 98% of SI-BONE, Inc. stock is owned by hedge funds and other institutional investors. Peregrine Capital Management LLC purchased 354,112 shares, amounting to 0.83% ownership. Other significant institutional owners include Calamos Advisors LLC, Victory Capital Management Inc., and Allianz Asset Management GmbH. Y Intercept Hong Kong Ltd and Universal Beteiligungs und Servicegesellschaft mbH also purchased new stakes in the first quarter.